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CON S EN SU S S T A T EMEN T
Consensus Statements of the American College of Veterinary Internal Medicine (ACVIM) provide the veterinary community with up-to-date infor-
mation on the pathophysiology, diagnosis, and treatment of clinically important animal diseases. The ACVIM Board of Regents oversees selection of
relevant topics, identification of panel members with the expertise to draft the statements, and other aspects of assuring the integrity of the process.
The statements are derived from evidence-based medicine whenever possible and the panel offers interpretive comments when such evidence is
inadequate or contradictory. A draft is prepared by the panel, followed by solicitation of input by the ACVIM membership, which may be incorpo-
rated into the statement. It is then submitted to the Journal of Veterinary Internal Medicine, where it is edited before publication. The authors are
solely responsible for the content of the statements.
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An update of the 2006 American College of Veterinary Internal Medicine (ACVIM) Small Animal
Consensus Statement on Lyme Disease in Dogs: Diagnosis, Treatment, and Prevention was pre-
sented at the 2016 ACVIM Forum in Denver, CO, followed by panel and audience discussion and
a drafted consensus statement distributed online to diplomates for comment. The updated consen-
sus statement is presented below. The consensus statement aims to provide guidance on the
diagnosis, treatment, and prevention of Lyme borreliosis in dogs and cats.
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1 | INTRODUCTION
Over the past decade, since the first ACVIM Small Animal Lyme
Consensus Statement1 was written, a broader understanding of the
large number of Borrelia species that exist, the variability of strains of
Borrelia burgdorferi sensu stricto (Bb), and the diversity of other patho-
gens carried by Ixodes and other ticks has been gained. The geographic
distribution of infected ticks has expanded because of bird migration,
Abbreviations: Bb, Borrelia burgdorferi sensu stricto; Bb-sl, Borrelia burgdorferi
sensu lato; BMDs, Bernese Mountain Dogs; CIC, circulating immune-
complexes; EBM, evidence-based medicine classification; ICGN, immune-
complex glomerulonephritis; LB, Lyme borreliosis; Osp, outer surface protein
(eg, OspA, OspC, OspF); PLN, protein-losing nephropathy; TBD, tickborne
disease(s); UPC, urine protein/creatinine ratio; VlsE, variable major protein-like
sequence, expressed.
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suburban sprawl, and climate changes. Additional diagnostic tests are
available to help rule out coinfections and other causes of clinical signs
potentially attributable to Lyme borreliosis (LB), help differentiate vac-
cinal from natural acute or chronic exposure anti-Bb antibodies, and
follow those antibodies that may wane post-treatment. Guidelines are
offered for management of nonclinical nonproteinuric Bb-seropositive
dogs and those with suspected clinical Lyme arthritis, Lyme nephritis,
or both. Prevention updates include discussion of acaricide products
provided as collars, topicals, or chewables that may facilitate owner
compliance as well as new vaccination updates.
What has not changed is the finding that most Bb-seropositive
dogs and cats show no clinical signs of illness, neither experimentally
(using the natural tick exposure model) nor in the field. Signs of Lyme
arthritis, seen in a small subset of infected dogs, are transient or
respond quickly to PO antibiotics. Signs of dermatologic, neurologic, or
cardiac manifestations as seen in human patients are rare and not well-
documented in dogs or cats. The most serious (putatively associated)
form of LB in dogs, Lyme nephritis, is less common than Lyme arthritis.
No experimental model to study its pathogenesis, treatment, and pre-
vention in over-represented (retriever) breeds has been developed, and
no validated staining techniques are available to prove that glomerular
immune-complexes are Lyme-specific in kidney biopsy specimens from
living dogs. Despite these limitations, strategies for empirical manage-
ment of Lyme nephritis are given, as recently offered by the Interna-
tional Renal Interest Society (IRIS) Glomerular Disease Study Group.2–5
The objectives of this consensus statement are to review the evi-
dence and provide findings and recommendations that address these
topics regarding Borrelia spp. infection in dogs or cats:
1. What species are most common and where are the endemic areas?
2. What are the most common clinical manifestations of LB?
3. What diagnostic tests to confirm Bb exposure are recommended
for clinically ill animals?
4. What treatments are recommended for clinically ill animals?
5. What testing is recommended for healthy animals?
6. Should treatments be offered for nonclinical, nonproteinuric sero-
positive dogs?
7. What prevention modalities are recommended?
This Lyme consensus update is best read in conjunction with the previ-
ous one,1 which includes many of the references for the original experi-
mental and field studies. The update initially was discussed during a
Special Interest Group presentation at the ACVIM National Forum in
2015. The authors conversed by phone and community emails with
draft findings presented at the ACVIM National Forum in 2016. The 6
authors each voted whether or not to support the summary statements
in the update. If a vote is not recorded with a statement, then the vote
of support was unanimous. For statements about which a consensus
could not be reached, the vote of the committee members is listed and
a brief explanation given for the dissenting votes. The update then was
provided to the general ACVIM and ECVIM memberships and the
Companion Animal Parasite Council and comments considered before
submission for publication. The evidence-based medicine (EBM) scale
for references, comments, and recommendations was used as data was
obtained from the following:
EBM-A: Randomized, controlled clinical trials in the
target species with spontaneous disease.
EBM-B: Randomized, controlled studies in the target
species with disease in an experimental setting.
EBM-C: Nonrandomized clinical trials, multiple case
series, other experimental studies, and important results
from uncontrolled studies.
EBM-D: Expert opinion, case reports, or studies in other
species.
2 | TOPIC 1: WHAT SPECIES ARE MOST
COMMON AND WHERE ARE THE ENDEMIC
AREAS?
2.1 | Topic 1a: Update on Borrelia spp. and associated
ticks
There are at least 52 Borrelia species,6 including 21 in the LB group
(B. burgdorferi sensu lato; Bb-sl; these gram-negative spirochetes gener-
ally migrate within the host interstitially), 29 in the relapsing fever
group (migrating hematogenously), and 2 undetermined members. In
dogs residing in North America, LB has only been associated with B.
burgdorferi sensu stricto (Bb), of which at least 30 subtypes or strains
exist, based on outer surface protein C (OspC) genotyping.7 The strains
appear host-specific; different strains are more common in people as
compared with dogs.7,8 In Europe, coinfections of Bb with other Bb-sl
strains (ie, B. garinii) may predispose dogs to illness.9 Other Bb-sl spe-
cies causing human LB (ie, B. mayonii10 in upper Midwestern states; B.
afzelii, B. bavariensis, B. garinii, and B. spielmanni in Europe9) are not
known to cause illness in dogs. The main tick vector for Bb is the 3-
host tick Ixodes scapularis in Northeastern, Mid-Atlantic, upper
Midwestern states, and adjacent areas of Canada11,12 (http://www.
capcvet.org/parasite-prevalence-maps. Accessed January 5, 2018);
I. pacificus in the Pacific states and Canada; and, I. ricinus in Europe.
Ixodes scapularis also may transmit B. mayonii10 in the upper Midwest
and adjacent Canada causing LB signs (with unusually high spirochete-
mia) and B. miyamotoi13,14 in the Northeastern, Mid-Atlantic, upper
Midwestern US and adjacent areas of Canada is a cause of tickborne
relapsing fever (TBRF) in humans but is not yet known in dogs.
Similarly, B. lonestari15,16 transmitted by Amblyomma and other ticks,
once thought to cause southern tick-associated rash infection (STARI)
in humans, has not been associated with illness in dogs. Relapsing fever
Borrelia species (B. hermsii in Northwestern states and adjacent
Canada;17 B. turicatae in Southern states;18,19 B. persica in the Middle
East and Asia20,21) have been described in sick dogs (B. persica also is
described in sick cats), and are transmitted by Ornithodorus soft argasid
ticks, which only feed for 15–90 minutes.
Most Borrelia species are transmitted transstadially within the tick;
some in the relapsing fever group22 (eg, B. miyamotoi23) also are
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transmitted transovarially. Ixodes larvae acquire Bb during their first
meal, usually in the summer,24 from a small mammal or bird. The spiro-
chete has numerous outer surface proteins (osp), and during feeding,
OspA, expressed by Bb and acting as a hook to the tick’s midgut, is
down-regulated as OspC expression increases, allowing spirochetes to
migrate from the midgut and enter the host, usually after 36–48 hours
of tick attachment.25 More than 30 OspC genotypes or strains are
found in nature (not all are pathogenic). Among 16 strains found in
New England, the most common ones in humans were types A, B, I, K,
and N, whereas the most common ones in dogs were A, B, F, I, and N.7
This finding impacts vaccine development for humans and dogs.
Other organisms transmitted by I. scapularis and potentially associ-
ated with clinical illness in humans, dogs, and cats (some agents) include
Anaplasma phagocytophilum,26 Ehrlichia muris,27 tickborne encephalitis
(Powassan) virus,28 F. tularensis, and possibly Bartonella spp.29,30 These
infections can mimic LB and if coinfections occur, may be associated
with increased morbidity.31 Additional Ixodid organisms causing illness
in humans (eg, Babesia microti, Babesia duncani, B. miyamotoi, and B.
mayonii) have not yet been associated with disease manifestations in
dogs or cats. A Babesia microti-like organism causes protein-losing
nephropathy (PLN) in dogs in Spain and Portugal and has been found in
foxes in North America.32,33
Statement: The panel recommends further research to
evaluate disease manifestations in dogs and cats because
of non-Bb Borrelia spp. [EBM-D] Coinfections must be
considered in those with suspected LB [EBM-C].
2.2 | Topic 1b: Geographic distribution and
epidemiology of Bb infection
The geographical persistence and spread of Bb is related to the 2-
year, 3-stage (larva, nymph, and adult) life cycle of its Ixodes spp. vec-
tor, which feeds on a variety of hosts. One blood meal occurs per
stage, and uninfected tick larvae hatch to feed on Borrelia-infected
reservoir hosts, principally mice, squirrels, shrews, birds (I. scapularis)
and lizards (I. pacificus).22 Within endemic geographical areas, the
prevalence of B. burgdorferi in nymphal or adult ticks can reach
approximately 50%.34–36 Although nymphs are likely responsible for
the majority of Bb transmission to humans and dogs because the
small size of this stage allows them to feed on the host undetected,
dogs may be less susceptible to transmission of Bb from infected
nymph versus adult infected ticks.37,38 Borrelia infection often occurs
in the warmer months as a result of the questing behavior of ticks
and the recreational habits of humans (owners) and their dogs.39
Later the same summer, nymphs molt to adults which feed on large
mammals, preferentially deer, but also dogs and humans. Adult Ixodes
ticks can be active in the fall, winter, and early spring when ambient
air temperatures exceed 48C (408F).40 Deer are important for the
maintenance, amplification, and spread of the tick population because
adult ticks mate on them.22 Thus, Borrelia-infected ticks may first
spread large distances by bird travel but then spread in a local area
by deer or other reservoir movement. With suitable vegetation and
ample reservoir hosts, Bb-infested ticks gradually will become estab-
lished in an area. Similarly, decreases in vegetation and reservoir
hosts, particularly deer, will result in a gradual decrease in disease.41
Prevalence estimates of LB in dogs are hindered by a lack of
demonstrative clinical signs and no national surveillance system for
companion animal diseases. However, screening tests for Bb antibod-
ies are widely used, and estimated canine Bb seroprevalence data at
the US state and county and Canadian province and territory levels
are available based on input from commercial diagnostic laboratories
through the Companion Animal Parasite Council (CAPC; http://www.
capcvet.org/parasite-prevalence-maps. Accessed on January 5, 2018;
Table 1). Lyme disease in humans has been a notifiable disease in the
US for many years although not every case is reported to the Cen-
ters for Disease Control and Prevention (Centers for Disease Control
and Prevention. CDC provides estimate of Americans diagnosed with
LB each year. http://www.cdc.gov/media/releases/2013/p0819-lyme-
disease.html. Press release August 19, 2013. Accessed on January 5,
2018. Reported cases of LB by state or locality, 2006–2016. Avail-
able at www.cdc.gov/lyme/stats/chartstables/reportedcases_statelo-
cality.html. Accessed on January 5, 2018.) and surveillance summaries
lag behind disease reporting. Underreporting of cases in humans is
more likely in highly endemic areas, whereas misclassification (overre-
porting) is more likely in nonendemic areas.42 The same may be true
for dogs. Travel history of sick or seropositive dogs is an important
historical question because cases in nonendemic areas may occur
after travel to or importation from endemic disease areas.
The main vector for Bb-sl in Europe is I. ricinus and the distribution
of LB follows its expansion.43 The highest prevalence was found in
central Europe with an increase of the infection rate of adult ticks from
west to east. At least 5 species (B. afzelii, B. garinii, B. burgdorferi s.s.,
B. spielmanii, and B. bavariensis) cause disease in humans.43 Different
species are found in questing ticks in different parts of Europe.44 These
different species lead to a wider variety of clinical signs in infected
humans in Europe compared with North America; whether or not this
is true for dogs is unknown.
Statement: LB is established in geographical areas in
North America and Europe, and is spreading, because of
persistent tick vectors and reservoir hosts [EBM-C]. The
estimated seroprevalence rates in dogs cannot be used
as estimates of LB because most dogs that are exposed
seroconvert, but do not develop clinical illness [EBM-C].
3 | TOPIC 2: WHAT ARE THE MOST
COMMON CLINICAL MANIFESTATIONS
OF LB?
3.1 | Topic 2a: Considerations for dogs in North
America
Most Bb-seropositive dogs show no clinical signs. The 2 main clinical
manifestations of Bb infection in dogs, Lyme arthritis (in the field and
experimentally) and Lyme nephritis (only in the field), were extensively
reviewed previously and are not presented in detail here.1,45–47
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Subclinical histologic evidence of mild-to-moderate synovial changes
and tick bite site perivasculitis and perineuritis are consistent findings
in dogs experimentally infected with Bb after tick exposure; the
changes seen are milder in 18-week old versus 6-week old exposed
puppies.38,48–50 Although neurologic signs were described in a few
seropositive dogs in the past,51 recent field studies showed no associa-
tion of neurologic signs in seropositive dogs, thus neuroborreliosis as
seen in human and equine52 patients is not well-documented in
dogs.53–56 Fatal myocarditis was described in Boxer pups with Bb-
positive immunohistochemistry, for which no other cause was found;57
there may be a genetic (breed) predisposition for autoimmune myocar-
ditis triggered by a Lyme antigen which mimics cardiac myosin.58 Lyme
carditis, although uncommon in people, typically is manifested as atrio-
ventricular block; this disease presentation also is poorly documented
in dogs. Orbital myositis is a rare finding in infected people and has
been reported in 1 dog.59
Statement: Neurologic and cardiologic manifestations of
LB in dogs are not well-documented [EBM-D].
3.2 | Topic 2b: European considerations; Bernese
Mountain Dogs in Europe
In Europe, numerous serosurveys in dogs from different countries
show a wide range of differences in seroprevalence. This is not surpris-
ing, considering the unequal distribution of ticks carrying Bb-sl. Little
information is available regarding clinical disease in dogs caused by
these organisms in Europe. Most studies show no association of sero-
positivity with clinical signs.60–64 One clinical study described 98 dogs
with clinical signs possibly attributable to LB (history of tick infestation,
lameness, neurological signs, nephropathy, lethargy, anorexia, fever).65
Of these, 21 dogs (21%) were Bb-sl-seropositive (higher seropreva-
lence than in healthy dogs and dogs showing non-LB clinical signs). In
13 of the 21 dogs, no other cause of illness was found after extensive
diagnostic evaluation, indicating a relationship between Bb-sl-
seropositivity and disease. However in none of the 13 dogs could spi-
rochetal DNA or viable spirochetes be detected.
Statement: It is not proven that European LB causes
clinical signs in dogs [EBM-D].
TABLE 1 Bb antibody seroprevalence totals in dogs in North America, 2017 (http://www.capcvet.org/parasite-prevalence-maps. Accessed on
January 5, 2018)
State #Positive/#tested; % State #Positive/#tested; % State #Positive/#tested; %
AL 122/37,125; 0.33 KY 666/50,644; 1.32 ND 591/12,804; 4.62
AK 3/59; 5.08 LA 33/17,017; 0.19 OH 2,687/214,195; 1.25
AZ 208/42,740; 0.49 ME 11,856/84,812;13.98 OK 118/36,923; 0.32
AR 41/19,657; 0.21 MDa 11,832/172,014; 6.88 OR 129/12,862; 1.00
CA 1,389/156,151; 0.89 MAa 38,448/248,335; 15.48 PAa 44,475/318,946; 13.94
CO 188/21,876; 0.86 MI 3,477/238,240; 1.46 RIa 2,782/21,696; 12.82
CTa 22,132/135,483; 16.34 MNa 11,524/137,235; 8.40 SC 748/61,934; 1.21
DEa 1,600/29,289; 5.46 MS 27/10,498; 0.26 SD 59/6,809; 0.87
DCa 1,069/11,496; 9.30 MO 204/61,677; 0.33 TN 455/59,693; 0.76
FL 1,548/209,288; 0.74 MT 13/1,038; 1.25 TX 584/221,599; 0.26
GA 349/95,670; 0.36 NE 43/7,465; 0.58 UT 11/640; 1.72
HI 22/7,869; 0.28 NV 16/3,345; 0.48 VT 4,724/32,657; 14.47
ID 5/632; 0.79 NHa 10,405/78,309; 13.29 VAa 21,141/270,527; 7.81
IL 7,003/232,469; 3.01 NJa 16,017/154,178; 10.39 WA 37/4,957; 0.75
IN 3,432/102,541; 3.35 NM 39/9,620; 0.41 WV 2,870/35,058; 8.19
IA 2,606/64,430; 4.04 NYa 35,955/326,326; 11.02 WIa 13,922/162,779; 8.55
KS 80/31,354; 0.26 NC 5,818/253,695; 2.29 WY 8/426; 1.88
Canada, available province/territory data
AB 1/533; 0.19 NB 61/857; 7.12 ON 1,915/82,886; 2.31
BC 0/180; 0.00 NF 1/146; 0.68 QC 865/22,847; 3.79
MB 621/17,824; 3.48 NS 302/1,523; 19.8 SK 1/36; 2.78
Highlighted states–2017 areas of interest. Also check maps (http://www.capcvet.org/parasite-prevalence-maps. Accessed on January 5, 2018) of
adjacent states for high seropositivity in contiguous counties.
aTwelve states reported in 2003 to account for 95% of cases.1
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Interestingly, Bernese Mountain Dogs (BMDs) in Europe are
more often Bb-sl-seropositive compared to dogs of other breeds.60,66
In 1 study, 58% of 160 healthy BMDs were seropositive, compared
with 15% seropositivity in healthy dogs of other large breeds with
long hair living in the same region.66 No reason was found as to why
the BMDs would be more prone to Bb-sl infection compared to
other dogs in the region with similar risk of exposure. In another
study of 200 randomly selected dogs admitted to 1 hospital, 13 were
BMDs and, of these, 12 (92%) were Bb-sl-seropositive, compared
with only 13 (7%) seropositive dogs of the remaining 187 dogs.60 In
this study, BMDs were more often coinfected with A. phagocytophi-
lum but the risk of infection with A. phagocytophilum alone was not
higher than in other dogs. This finding indicates that a higher
exposure of BMDs to ticks could not be the reason for the high Bb-
sl-seroprevalence. In both studies, there may have been a breed pre-
disposition of BMDs for Bb-sl infections. Furthermore, it is interesting
that both of the studies showing higher Bb-sl-seroprevalence were
performed in close proximity to each other in central Europe
(Switzerland and southern Germany), the region where the highest
prevalence of Bb-sl infested ticks was found.67 One might speculate
about a regional effect, a close genetic relationship among the posi-
tive dogs, a genetic predisposition for infection (as was found in
Beagles68) or a unique infectious species of Bb-sl in the area.
Statement: Although not associated with illness, BMDs
in central Europe are more often Bb-sl-seropositive
than other breeds [EBM-C].
3.3 | Topic 2c: Considerations in cats
Cats living in Bb-endemic areas are sometimes seropositive.1,69–73 Cats
infested with I. scapularis containing Bb develop serum antibodies
against the organism and DNA of Bb has been amplified from skin
biopsy specimens taken from tick attachment sites.74–76 Ticks removed
from cats in endemic areas have been positive for Bb.70 These studies
suggest that cats can be infected by Bb and that Ixodes spp. are the
likely vectors for Bb in cats in the United States.
Cats experimentally infested with Ixodes spp. have not developed
detectable clinical signs of disease, even if infested twice.74–76 Cats in
Bb-endemic areas may have clinical signs potentially referable to Bb
infection but to date, no published studies document the organism as
the cause of illness.69 It is difficult to prove causation of illness
associated with Bb in cats because Ixodes spp. also are the vector for
A. phagocytophilum. Anaplasmosis has been documented in cats in 2
studies in a Bb-endemic region.77,78 Clinical signs of anaplasmosis and
borreliosis are similar to each other in dogs and people, and this may
be the case for cats as well.
It is proposed by some that cats fail to develop borreliosis because
they are more efficient at removing infected ticks. However, serocon-
version occurs in naturally exposed and experimentally infested cats
suggesting that infection occurs, which should be blocked if ticks were
promptly removed. At this time, evidence excluding borreliosis as a
cause of clinical illness in cats is as weak as the data indicating
causation.
Statement: Although cats may be Bb-seropositive, it is
unknown if Bb infection causes illness in cats [EBM-D].
4 | TOPIC 3: WHAT DIAGNOSTIC TESTS TO
CONFIRM Bb EXPOSURE ARE
RECOMMENDED FOR CLINICALLY ILL
ANIMALS?
4.1 | Topic 3a
In dogs, serology is the only recommended modality to evaluate for
exposure to Bb (Table 2). Validated serologic tests for Bb exposure in
North America include in-house and reference laboratory C6-based
TABLE 2 Bb antibody tests available
Commonly
used
Differentiates vaccinal
versus natural
exposure antibody Qualitative Quantitative Bedside
Differentiates
acute
versus chronic
infection
Heartworm antigen,
antibodies to
Anaplasma
and Ehrlichia spp.
Whole cell IFA or ELISA No X
IgM and IgG No X Possibly
Western Blot Possibly X Semi Possibly
SNAP4DxPlus (IDEXX) X Yes, VlsE (C6) X X X
Quant C6
a (IDEXX) X Yes, VlsE (C6) X
VetScan Rapid (Abaxis) X Possibly; VlsE, OspC,
Flagellin
X X
AccuPlex4 (Antech) X Possibly; OspA, OspC,
OspF, p39, SLP
X Possibly X
Multiplex (Cornell) X Possibly; OspA, OspC, OspF X Possibly
aThe Quant C6 is not considered a screening test (see text).
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testing (SNAP4Dx and SNAP4DxPlus [IDEXX Laboratories, Westbrook,
Maine]; Lyme Quant C6 [IDEXX Laboratories, Westbrook, Maine]),79–81
the VetScan Canine Lyme Rapid assay (Abaxis North America, Union
City, California), the AccuPlex4 test (Antech Diagnostics, Irvine, Califor-
nia),82,83 and the Multiplex test (Cornell University Animal Health Diag-
nostic Center, Ithaca, New York).84,85 Few studies compare different
Bb antibody assay performance. In 1 study using Western blot as the
gold standard, a commercially available kit based on the C6 antigen was
found to be more accurate than a commercially available multiplex fluo-
rescence (AccuPlex4 [Antech Diagnostics, Irvine, California]) assay.86 In
other studies of dogs experimentally infected with Bb, anti-OspC anti-
bodies were detected before those against other peptides, suggesting
that the multiplex assay may be more sensitive in acute cases of
LB.83–85 This may not be clinically relevant because infected dogs do
not typically present acutely.1
Quantitative Bb antibody assays are available for C6 (Lyme Quant
C6 [IDEXX Laboratories, Westbrook, Maine]), and OspA, OspC, and
Osp F antibodies (Multiplex [Cornell University Animal Health Diagnos-
tic Center, Ithaca, New York]). Only 1 panelist recommends the routine
use of a quantitative C6 test for healthy nonclinical, nonproteinuric
qualitatively seropositive dogs. The dissenting panelists stated that
there is insufficient published evidence that higher titers predict illness
or are associated with future illness to advocate routine recommenda-
tion of this test in healthy dogs.
Antibodies against C6, VlsE (variable major protein-like sequence,
expressed), and OspF indicate natural exposure because these antigens
are not present in any Bb vaccines. Vaccines that induce OspC antibod-
ies interfere with this marker of natural exposure on Western blot,
AccuPlex4, VetScan and Multiplex tests. After experimental natural
exposure, OspC antibodies increase by 2–3 weeks, and wane in 3–5
months (without re-exposure), whereas OspF antibodies increase by 6–
8 weeks and remain increased in untreated carriers.83–85,87 The OspC
antibodies probably increase again in field conditions (ie, re-exposure is
a natural booster), thus finding OspC antibodies in a nonvaccinated
dog may indicate recent exposure or re-exposure, without specifying
when the dog was first infected in its life. The OspA antibodies usually
are a marker for vaccination, but they may develop transiently in early
infection,83,85 or possibly later during chronic infections, as seen in
infected humans, because Bb displays antigenic variation, and
expresses its antigenic repertoire over time to avoid host
immunity.88–91 The C6 result has been shown to wane after
treatment;92–94 OspF antibodies also may wane.95 Determination of
quantitative titers to C6 (or potentially OspF), pre- and 3
94 to 6 months
post-treatment, were recommended by 4/6 panelists to check for a
decrease after treatment as an indicator of decreased antigenic load,
and to establish a new baseline for future comparison, because qualita-
tive tests may stay positive a long time after treatment.96 An increased
result over baseline may indicate re-exposure or relapse. The dissenting
panelists state there is no published evidence that quantitative test
results predict current illness, the potential for development of chronic
disease, or differentiate reinfection from reactivation of a chronic
infection.
Panelists did not recommend whole cell ELISA, immunofluorescent
antibody (IFA) testing, or Western blot testing because of possible
cross-reactions with other spirochetal infections, or the IgM versus IgG
antibody testing because dogs do not present with acute illness before
seroconversion.1
Statement: Panelists agreed that the presence of
antibodies against C6, VlsE, Osp C (in nonvaccinates),
OspF, or some combination of these indicates exposure
to Bb, but is not proof of cause of clinical signs, nor can it
be used as a predictor for development of future clinical
signs [EBM-C].
4.2 | Topic 3b
In cats, several studies document antibodies against Bb occur in the
serum of cats that are naturally exposed or infected with Bb after being
experimentally infested with I. scapularis.70–76 Recent studies measured
antibodies against the C6 peptide using kits labeled for use with dog
serum, which do not use species-specific reagents (SNAP4Dx and
SNAP4DxPlus [IDEXX Laboratories, Westbrook, Maine]).75,76 In 2
recent studies in which cats were experimentally infested with wild
caught I. scapularis, 8 of 13 cats seroconverted.75,76 Duration of posi-
tive test results varied, but was as short as 1 week in 1 cat.75 In 1 of
the studies, skin biopsy specimens also were tested for Bb DNA by
PCR assay and 3 of 9 cats were PCR positive but remained C6 antibody
negative over the 84-day study.76
Statement: The panel believes that further optimization
experiments should be performed before this kit
(SNAP4Dx and SNAP4DxPlus [IDEXX Laboratories,
Westbrook, Maine]) can be recommended for routine
use with cat serum [EBM-D].
5 | TOPIC 4: WHAT TREATMENTS ARE
RECOMMENDED FOR CLINICALLY ILL
ANIMALS?
5.1 | Topic 4a: Treatment of lyme arthritis in dogs
The classical presentation of LB is an acute monoarticular or polyarticu-
lar lameness with joint swelling, fever, lethargy, and mild local lymphad-
enopathy,1 usually in young, often large breed dogs with an active/
outdoor lifestyle, but depending upon geographical location, is seen in
other types of dogs. Treatment is based on treating infection and man-
aging pain. Experimentally, the illness is self-limiting, and in the field
typically a rapid response to antibiotics occurs within 1–2 days.
Many antibiotics, used both parenterally and PO, show efficacy
in treating LB (Table 3).69,98 Beta-lactams and tetracyclines have been
shown to be effective for lessening clinical signs of LB in dogs.
Because of the protracted biological behavior of Borrelia, a long
course of antibiotics (4 weeks) is indicated.95,99–102 The best drug,
dosage, and duration of treatment for affected dogs are unknown.
Panelists recommend doxycycline as the first choice in most sick
dogs with suspected LB because of the ease of administration,
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efficacy against coinfections (eg, Anaplasma, Ehrlichia, Leptospira spp.),
and purported antiarthritic, anti-inflammatory properties.1,103 Doxycy-
cline was not associated with dental staining in children104 and is
labeled for use in puppies and kittens as early as 4 weeks of age in
some countries. However, although not a recommendation of the
panelists, some veterinarians in the field recommend use of amoxicil-
lin for doxycycline-sensitive or growing dogs. Recently, cefovecin105
(2 injections, 14 days apart) was shown to be as efficacious as 4
weeks of doxycycline or amoxicillin.95 Panelists agreed that this
option could be considered for dogs intolerant of tetracyclines.
Despite reports that 4 weeks of high dose treatment (10 mg/kg dox-
ycycline q12h) did not clear all organisms in all dogs,101,102 most vet-
erinarians treat for 4 weeks1 and many use a lower dosage of
10 mg/kg doxycycline q24h or divided q12h. Relapse seen in both
dogs and humans101,102,106–108 may be caused by coinfection or rein-
fection, especially with other Bb strains.109
Chronic Lyme arthritis is not well-documented in dogs and there is
no evidence to support treatment beyond 1 month. In humans, the
treatment of persistent clinical signs attributed to LB remains contro-
versial (CDC website: http://www.cdc.gov/lyme/. Accessed on January
5, 2018; IDSA website: http://www.idsociety.org/Lyme/. Accessed on
January 5, 2018; ILADS website: http://www.ilads.org/. Accessed on
January 5, 2018).91,98,106,108,110,111 A recent randomized, double-blind,
placebo-controlled trial in Europe showed no difference in quality of
life in those treated short-term versus long-term.111
Response to antibiotic treatment in dogs presenting with signs
of acute arthritis should be rapid (1–3 days) if the clinical signs
are a consequence of LB. Analgesics should be considered (eg,
gabapentin for neuropathic pain) as needed. Nonsteroidal anti-
inflammatory drugs may be less preferable, so as to avoid a neces-
sary “wash-out” period to decrease risk of gastrointestinal ulcera-
tion, should subsequent treatment with glucocorticosteroids be
indicated for suspected immune-mediated polyarthropathy in non-
responsive dogs. If relapse occurs before or after completion of
antibiotic treatment, additional diagnoses should include other
infectious disease agents, immune-mediated disease, soft tissue
trauma (eg, ligamental or meniscal tears), septic arthritis, or degen-
erative joint disease.1
Statement: Panelists agreed that Lyme arthritis be
treated for 4 weeks with antibiotics (doxycycline pre-
ferred) [EBM-D].
5.2 | Topic 4b: Treatment for Bb-seropositive dogs
with PLN
The nephropathy putatively associated with borreliosis is an immune-
complex glomerulonephritis (ICGN).112–115 No validated staining tech-
niques are available to prove that glomerular immune complexes found
in kidney biopsy specimens are Lyme-specific in the living dog, and
diagnosis depends on Bb-seropositivity in a dog with PLN for which no
other cause is found. No experimental model for Lyme nephritis is
available, and it is difficult to study treatment protocols. Recommenda-
tions are based on antimicrobial treatment and standard diagnostic and
treatment protocols for ICGN and PLN, as recommended by the IRIS
Canine Glomerulonephritis Study Group.2–5,116–118 Proteinuria concur-
rent with seropositivity for an infectious agent with the potential to
incite glomerular disease does not necessarily document a cause and
effect relationship, even if clinical signs (eg, lameness) are seen.
Only<30% of dogs with Lyme nephritis have a history of past or con-
current Lyme arthritis.2,5,51,112 Proteinuria is an uncommon finding,
seen in <2% of Bb-seropositive dogs.119 Antibodies against Bb may be
coincidental and a marker for wildlife exposure, because clinical signs
(eg, lameness, proteinuria) attributed to LB may be caused by coinfec-
tion (eg, Ehrlichia, Anaplasma, Babesia, Bartonella, other Borrelia spp.,
Rocky Mountain spotted fever, heartworm, leptospirosis) or tick paraly-
sis. Response to antibiotic treatment also is not proof of causation (eg,
doxycycline may treat coinfections and has anti-inflammatory and anti-
arthritic properties sufficient to cause resolution of clinical
signs).92,99,100,106 Besides infectious causes, PLN may be associated
with neoplasia, amyloidosis, as well as genetic, toxic, or other causes.
Thus, a thorough diagnostic evaluation still is warranted to rule out
other diseases, and to stage and to characterize possible complications
of PLN (eg, hypertension, thromboembolic events, nephrotic syndrome,
and renal failure).2,116
For clinically stable seropositive dogs with mild changes of PLN (ie,
uncomplicated nonprogressive renal proteinuria or mild
TABLE 3 Antibiotics used in the treatment of LB
Antibiotic Duration of Use Frequency Route Dosage
Doxycycline or minocyclinea 30 days 1–2 times daily PO or IV 10 mg/kg
Amoxicillin 30 days 3 times daily PO 20 mg/kg
Azithromycin 10–20 days Once daily PO 25 mg/kg
Clarithromycin 30 days 2 times daily PO 7.5–12.5 mg/kg
Erythromycin 30 days 2–3 times daily PO 25 mg/kg
Cefotaxime 14–30 days 3 times daily IV 20 mg/kg
Ceftriaxone 14–30 days Once daily IV or SC 25 mg/kg
Cefovecin 28 days 2 times, 14 days apart SC 8 mg/kg
aDoxycycline or minocycline are favored choices; minocycline is absorbed better without food.97
LITTMAN ET AL. Journal of Veterinary Internal Medicine | 893
hypoalbuminemia, without azotemia) recommendations include antimi-
crobial treatment, evaluation for evidence of other possible causes of
proteinuria (eg, coinfections, neoplasia, genetic diseases), and manage-
ment of proteinuria, hypertension, and hypercoagulopathy based on
established standard-of-care guidelines including a renin-angiotensin-
aldosterone system inhibitor (angiotensin-converting enzyme inhibitor
or aldosterone receptor (RAAS) blocker), antithrombotics, protein- and
phosphorus-restricted diets based on IRIS staging, omega-3 fatty acids,
and antihypertensives if needed.2,3,117 For dogs with more severe, per-
sistent, or progressive glomerular disease, or complications such as
vomiting, dehydration, edema, effusions, or worsening azotemia, addi-
tional recommendations include antiemetics, crystalloids or colloids,
aldosterone antagonist diuretics, phosphate binders, and treatments for
chronic kidney disease as needed.2,3,117 In addition, immunosuppres-
sive agents are indicated if there is biopsy-confirmed evidence of an
active immune-mediated pathogenesis (eg, electron-dense deposits by
transmission electron microscopy, unequivocal immunofluorescent
staining in the glomeruli),4,120 or even without biopsy confirmation in
nonresponders or those with rapid progression, severe azotemia (serum
creatinine concentration>5 mg/dL) or severe hypoalbuminemia (serum
albumin concentration<2.0 g/dL).2,5,121
For ICGN with profound proteinuria, hypoalbuminemia, nephrotic
syndrome, or rapidly progressive azotemia, single drug or combination
treatment consisting of rapidly acting immunosuppressive agents (Table
4) is recommended in addition to antimicrobials and standard PLN
treatments and diets.2–5,117,122,123 Immunosuppressive treatment is not
without risk, especially in cases with concurrent diabetes mellitus, pan-
creatitis, active or latent bacterial or fungal infections, uncontrolled
hypertension, hepatic dysfunction, or bone marrow suppression.
Another relative contraindication is a breed with known inherited
glomerulopathy.
The IRIS Study Group recommended mycophenolate as the first
immunosuppressive employed, perhaps with a tapering dose of prednis-
olone in dogs with acute rapidly progressive glomerular disease.4 To min-
imize adverse effects of glucocorticoids, they should not be the sole
agent and should be tapered as quickly as possible. Other immunosup-
pressive drugs (Table 4) are also anecdotally deemed efficacious for
ICGN. Experiential evidence suggests that mycophenolate results in
more remissions and long-term survival in dogs with ICGN.4 For stable
or slowly progressive glomerular diseases, the Study Group recom-
mended mycophenolate or chlorambucil alone or in combination with
azathioprine on alternating days. For mycophenolate-intolerant dogs,
consensus was lacking for the next preferred agent. Individual case varia-
tion and cost of medication may influence choice of treatment. For situa-
tions with extreme financial constraints, a short course of prednisone
was suggested (1 mg/kg q12h for 4 days with a 2-week taper).4
For both rapidly or slowly progressive forms of ICGN, therapeutic
efficacy is assessed serially by monitoring proteinuria, blood pressure,
serum albumin concentration, and kidney function tests. In the absence
of overt adverse effects, at least 12 weeks of immunosuppressive (non-
steroidal) drug treatment should be undertaken before altering or aban-
doning an immunosuppressive trial. Panelists did not agree on the
duration of antibiotic treatment, which ranged from 1 to 3 months, or
longer if subsequent Quant C6 antibody concentrations did not wane
appropriately.
Statement: Panelists agreed that Bb-seropositive dogs
with PLN be treated with antimicrobials as advised
above and that clinicians follow the guidelines for the
standard diagnostic tests and treatments for ICGN and
PLN as recommended by the IRIS Canine Glomerulo-
nephritis Study Group [EBM-D].
TABLE 4 Recommended dosages and adverse effects of representative immunosuppressive drugs for management of immune–complex glo-
merular disease
Drug Dosage Main adverse effects Mode of action
Mycophenolatea 5 mg/kg q12h PO and increase to
10 mg/kg if no GI upset
Gastrointestinal upset Antagonizes guanosine metabolism
Prednisolonea 1mg/kg q12h PO for 4–5 days then
taper as soon as possible
Polyuria, polydipsia, polyphagia,
thromboembolism, muscle wasting,
induction of liver enzymes, panting,
adrenal suppression, gastric ulcera-
tion
Inhibition of phospholipase A2,
reduction in cytokine release,
inhibition of neutrophil migration,
down regulation of Fc receptor
Azathioprine 2 mg/kg q24h PO for 2 weeks, then
1–2 mg/kg q48h
Gastrointestinal upset, myelosuppres-
sion, acute pancreatitis, hepatotoxi-
city, GI disorders, infection,
malignancy
Antagonizes purine metabolism
Cyclosporine 5–20 mg/kg q12h PO (taper dose
upward from low to high to avoid GI
complications)
Gastrointestinal upset, gingival
hyperplasia
Calcineurin inhibitor
Chlorambucil 0.2 mg/kg q24–48h PO Gastrointestinal upset,
myelosuppression
Alkylating agent
Cyclophosphamide 50 mg/m2 4 days/week PO, or as
pulse treatment 200–250 mg/m2
every 3 weeks
Myelosuppression, GI upset,
hemorrhagic cystitis, infection
Alkylating agent
aMycophenolate is a favored choice, with or without corticosteroids (see text).
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5.3 | Topic 4c
Because borreliosis in cats has never been confirmed in a single cat,
the optimal treatment plan is unknown. In cats with suspected anaplas-
mosis, clinical signs rapidly resolve after doxycycline is administered at
5 mg/kg q12h or 10 mg/kg PO q24h for 14–28 days.77,78 Whether or
not these cats also were infected with Bb cannot be determined. Based
on studies of acute borreliosis in dogs, these doxycycline protocols are
likely to be effective in cats as well.
6 | TOPIC 5: WHAT TESTING IS
RECOMMENDED FOR HEALTHY ANIMALS?
Panelists (5/5) recommended that a qualitative Bb antibody assay be
included with annual wellness and preventive care for healthy dogs
living in or near endemic areas in North America (there is no evidence
to support screening healthy cats for Bb antibodies). Screening for Bb
antibodies allows: (1) follow-up proteinuria screening for all seroposi-
tive dogs and early intervention for possible Lyme nephritis (see
treatment), (2) follow-up minimal data base including CBC and serum
biochemistry to identify cytopenias and kidney disease associated
with tick and wildlife exposure, (3) identification of seropositive dogs
(sentinels) that may indicate risk of exposure of humans, horses, cats
or other dogs in the area and the need for modification of preventive
protocols; and, (4) recognition of successful preventive strategies in
high risk areas. Panelists identified potential pitfalls when screening
healthy dogs, including the potential for overuse of antibiotics in rare
dogs with false positive assay results, overuse of antibiotics in healthy
dogs that would never develop LB, assay expense, induction of anxi-
ety in the owner, and the additional time necessary for owner
education.1
Statement: It is recommended to screen all healthy dogs
that live in, live near, or travel to Bb-endemic areas in
North America for Bb antibodies. It is recommended to
screen all Bb-seropositive dogs for proteinuria [EBM-D].
7 | TOPIC 6: SHOULD TREATMENTS BE
OFFERED FOR NONCLINICAL,
NONPROTEINURIC SEROPOSITIVE DOGS?
This topic is still controversial; 4/6 panelists do not routinely recom-
mend treatment for such dogs (Table 5),96,124 stating that: (1) this prac-
tice potentially promotes overuse of antibiotics; (2) no data exists
proving treatment of healthy dogs is associated with decreased risk of
illness; (3) Bb may not be cleared from all tissues with treatment; and,
(4) reinfection may commonly occur in dogs in endemic areas.
Seropositivity indicates tick and wildlife exposure and possible coinfec-
tion(s). Tick control and possible vaccination should be readdressed
(see below). Panelists in North America (5/5) recommend reevaluation
for proteinuria at least 2–3 times per year, even if the dog is treated
with antibiotics, because clearance may not occur, and because the
pathogenesis of Lyme nephritis is unknown.
If a seropositive dog is nonclinical and nonproteinuric, there is no
current evidence-based data that a quantitative C6 antibody test
(Lyme Quant C6 [IDEXX Laboratories, Westbrook, Maine]) result
helps decision-making regarding whether antimicrobial treatment is
warranted. The magnitude of Quant C6 is not predictive of illness. A
majority of untreated nonclinical nonproteinuric seropositive dogs
probably have high concentrations, as do experimentally infected
dogs, which all remain nonclinical. In the absence of clinical signs
increased Quant C6 may indicate exposure and a robust immune
response to the organism.96,124 Some dogs may eventually either
clear the organism or remain nonclinical carriers, as did experimental
dogs.
Dogs that show clinical signs of illness are a small subset of those
with high Quant C6 results. Correlation exists between the magnitude of
quantitative C6 and circulating immune-complex concentration.
114 One
panelist recommends that nonclinical dogs with high C6 results be given
a therapeutic course of doxycycline, possibly with a repeat quantitative
C6 performed in 3–6 months to document a new baseline result for com-
parisons if indicated in the future. Response to treatment is associated
with a decrease in Quant C6. Evidence is lacking as to what degree of
TABLE 5 Some pros and cons of treatment of all nonproteinuric, nonclinical seropositive dogs
Pros Cons
Treatment of possible Bb-associated periarticular inflammation Treatment is not needed if periarticular inflammation is not present; older
(18 week old) infected puppies showed milder histologic changes than
younger (6 week old) infected puppies
Treatment of possible coinfections Treatment is not needed if coinfection is not present
Possible prevention of future Lyme arthritis or Lyme nephritis There is no ability to monitor the response to treatment if the dog is truly
nonclinical; the vast majority of Bb-seropositive dogs never become ill nor
proteinuric
Unnecessary owner cost
Overuse of antibiotics may cause microbial resistance in the environment at
large
Possible adverse effects of treatment
Possible laxity in checking for proteinuria in carriers, even though they may
not all be cleared with treatment
Theoretically, a subclinically infected dog may be in a premunitive state that
could be protective, at least for that particular strain
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reduction is considered acceptable as compared with being indication
for continued treatment in the absence of clinical signs. The argument
for treating until Quant C6 results wane by at least 50% is that the orga-
nism may never be cleared as it enters “protected” collagen tissue, and
may develop into a latent cystic or L-form. Clinicians who treat believe
treatment may lessen the likelihood of future development of immune-
complex disease such as ICGN or nonclinical histologic changes found in
experimental dogs (eg, arthritis, perivasculitis, and perineuritis), although
this has never been confirmed by a controlled study.
Although anecdotally owners have reported improved well-being
after antibiotic treatment in nonclinical dogs, without randomized
placebo-controlled clinical trials it is unknown if the perceived improve-
ment is related to decreased subclinical disease from Bb, anti-
inflammatory properties, treatment of other subclinical disease, or is
merely a placebo effect.
Statement: Most (4/6) panelists do not routinely recom-
mend antimicrobial treatment for nonclinical nonprotei-
nuric Bb-seropositive dogs [EBM-D].
8 | TOPIC 7: WHAT PREVENTION
MODALITIES ARE RECOMMENDED?
8.1 | Topic 7a: Tick control
Prevention of Bb infection and development of LB is multifaceted. The
simplest and yet the most difficult step to achieve is tick prevention.
Ticks and the wildlife that carry ticks are in ever increasing proximity to
dogs and people. Frequent tick checks and removing ticks as soon as
they are identified is of utmost importance, although difficult in pets
with long or dark hair. Perimeter control is equally important. Ixodes
scapularis preferentially live under hardwood forest canopy and in the
underlying leaf litter.125–128 At least in the home environment, minimiz-
ing chances for tick inhabitation means keeping lawns cut short, clean-
ing areas of brush and weeds, and using wood chips in gardens.
Improved landscaping helps pets avoid ticks questing in vegetation and
brush (Centers for Disease Control and Prevention National Center for
Emerging and Zoonotic Infectious Diseases (NCEZID) Division of
Vector-Borne Diseases (DVBD). Preventing ticks in the yard. https://
www.cdc.gov/lyme/prev/in_the_yard.html. Accessed on January 5,
2018). Daily tick checks provide timely removal with a hemostat,
tweezers, or tick removal device, by grasping the tick close to its
attachment on the skin, and retracting slowly but steadily. Kennels
should be monitored and treated for Rhipicephalus infestations to
decrease risk of infection with other tickborne diseases (TBDs). Tick
type may be identified by checking for the anal groove of Ixodes or
with images available on-line (University of Rhode Island at
http://www.tickencounter.org/tick_identification. Accessed on January
5, 2018). In Bb-endemic areas, if a person removes an engorged Ixodes
tick, it is recommended that person take a 1-day dose of doxycycline
within 72 hours to help prevent LB.110 No such study has been done in
dogs regarding prevention of LB or other TBDs that are sensitive to
doxycycline.
Whether Bb vaccines are used or not, there is strong consensus
(6/6) that tick control must be used not only to help prevent LB but
also the many other TBDs in Bb-endemic areas for which there are no
vaccines available. Because ticks can become active even during the
winter if temperature increases above 408F (48C),40 year-round tick
prevention is advocated. Many products both topical and oral are avail-
able that have label claim against I. scapularis and currently are on the
market. This panel does not recommend any individual product, but
those that quickly kill or prevent attachment and feeding by the tick
are preferable. Borrelia burgdorferi generally is not transmitted until at
least 36–48 hours after tick attachment,25 but other TBDs may be
transmitted more rapidly, and prevention of tick attachment (eg, with
amitraz129 or permethrins130–134) or a relatively fast kill after attach-
ment (eg, with isoxazoline products135–139) is preferred over use of
fipronil, which does not kill the tick until after it has been attached for
24 hours. Fluralaner killed almost 90% of ticks by 4 hours, 98% by 8
hours, and 100% at 12 hours after application.139 Tick collars should be
applied tightly enough to have contact with skin, not just hair. Topical
permethrins should not be used on or near cats. The new PO (hydroly-
sate chewable) isoxazoline products, which kill at least some of the tick
species studied to date within 8 hours of attachment by binding to
tick-specific neurotransmitter gamma-aminobutyric acid-gated chloride
channels which mammals do not have, are easy to administer, increase
compliance, and may help coverage for dogs that swim or get bathed
often.140,141 Combinations of products with different mechanisms also
may be used. See Table 6 for a comparison of some commonly used
tick control products.
In 1 study of 9 cats infested with wild-caught I. scapularis twice, 2
cats seroconverted after the first infestation, became seronegative, and
then seroconverted again after the second infestation suggesting a new
primary infection.76 Thus, it appears that Bb infection does not induce
preventive immunity in cats and repeated infection can occur without
tick control. In another study of naturally exposed cats with and without
clinical signs referable to borreliosis, whether or not the owner pur-
chased a tick control product was recorded.142 When serum antibodies
against Bb and A. phagocytophilum were measured, it was shown that
purchase of a tick control product did not lessen the likelihood of detect-
ing serum antibodies. Whether this finding related to lack of efficacy or
failure of compliance could not be determined from the study. In dogs,
use of tick control products appropriately can lessen the risk of develop-
ing antibodies against Bb and A. phagocytophilum, and this is likely to
occur in cats as well if the products are used as directed.135,137,143
Statement: Whether Bb vaccines are used or not, there
is strong consensus that tick control must be used not
only to help prevent LB but also to prevent many other
TBDs for which there are no vaccines available [EBM-C].
8.2 | Topic 7b: Bb vaccination
The efficacy of tick control products is excellent, as proven by preven-
tion of seroconversion after tick exposure challenge.135,137,143 How-
ever, compliance for using these products properly is an ongoing
problem, and many veterinarians in Bb-endemic areas also recommend
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Bb vaccinations, although the latter are not as efficacious when used
alone. In the United States, all currently available Bb vaccines (Recom-
bitek Lyme. Merial Limited. Duluth, Georgia; Lymevax Zoetis, Florham
Park, New Jersey 07932; Duramune Lyme Boehringer Ingelheim Vet-
medica, Inc, St. Joseph, Missouri 64506; Nobivac Lyme, Merck Animal
Health, Summit, New Jersey 07901; Vanguard crLyme, Zoetis, Florham
Park, New Jersey 07932; Table 7) induce anti-OspA antibodies, which
when imbibed by a feeding tick will attack spirochetes which express
OspA wihin the tick’s midgut, halting transmission. Anti-OspA titers are
however not boosted by natural exposure and wane in vaccinates,
allowing infection of the host. Anti-OspC antibodies induced by biva-
lent bacterin vaccines (Lymevax Zoetis, Florham Park, New Jersey
07932; Duramune Lyme Boehringer Ingelheim Vetmedica, Inc, St.
Joseph, Missouri 64506; Nobivac Lyme, Merck Animal Health, Summit,
New Jersey 07901) or the chimeric recombinant vaccine (Vanguard
crLyme, Zoetis, Florham Park, New Jersey 07932), and boosted by nat-
ural exposure, can eliminate transmitted organisms that express OspC.
Panelists who routinely recommend Bb vaccines for dogs (in addition
to tick control) cite high efficacy, safety, and good duration of immunity
(Jody Sandler, DVM, Director of Veterinary Services. Guiding Eyes for
the Blind, Yorktown New York. Personal communication).144–150 Vacci-
nal duration of immunity however appears inconsistent and less than
ideal for some vaccines studied.83,151 Six-month boosters have been
proposed147,151 during the initial year (although no safety studies are
available) and it is unknown whether or not to suggest 6-month versus
annual boosters thereafter. Vaccine failures were found only 22 weeks
after OspA subunit or bacterin vaccination.83 The most recently
licensed Bb vaccine (Vanguard crLyme, Zoetis, Florham Park,
New Jersey 07932) was shown in prerelease studies to induce OspA and
OspC antibodies against 7 Bb strains, which may afford broader protec-
tion. In a 15-month duration-of-immunity study completed by the manu-
facturer, vaccinated dogs were less likely (7/16 dogs seroconverted) than
control dogs (14/16 dogs seroconverted) to develop evidence of Bb
infection after tick challenge (Zoetis Study B864R-US-12–037).
The routine use of Bb vaccinations in Bb-endemic areas in North
America was recommended by 3/6 panelists, for seronegative as well
as healthy nonclinical, nonproteinuric seropositive dogs, because no
natural immunity occurs from previous infection, partly because of the
TABLE 6 Examples of tick control products in the United States
Productsa T, F Swim Cats
Prevents
attachment Age, BW
Pregnancy
lactation Frequency
Topicals
Fipronil
Frontline T, F Yes Yes No 8 week Consult vet Monthly
Permethrins T, F, M Yes No Yes Consult vet Monthly
Activyl T1 8 week, 4#
Advantix II 7 week, 4#
Parastar1
Vectra 3D
Revolution Does not kill Ixodes, therefore Revolution is not recommended for tick control
Collars
Amitraz T only No No Yes 2–3 months
Preventic 12 week Consult vet
Permethrins T, F, M No Consult vet
Scalibor No Yes 12 week 6 months (2–3 week lag)
Seresto Yes  10 week cats 7 week, 4# 8 months
Chewables
Isoxazolines T, F Yes No, but relatively fast kill
NexGard No 8 week, 4# Consult vet 1 month
Simparica No 1 month
Bravectob Topical available 6 months Yes 3 months; but only
2 months for Amblyomma
BW: body weight; F: fleas; M: mosquitos; T: ticks; wk: weeks; #: pounds.
aProducts, ingredients, and manufacturers: Activyl Tick Plus (indoxacarb, permethrin; Merck Animal Health, Intervet Inc, Roseland, NJ 07068). Bravecto
(fluralaner; Merck Animal Health, Intervet Inc, Summit, NJ 07901). bBravecto topical is available for cats and dogs; oral chewable Bravecto is only avail-
able for dogs. Frontline Plus (fipronil, S-methoprene; Merial Limited, Duluth, Georgia 30096). Preventic collar (amitraz; Virbac Corporation, Fort Worth,
Texas 76137). K9 Advantix II (imidacloprid, permethrin, pyriproxyfen; Bayer Healthcare LLC, Animal Health Division, Shawnee Mission, Kansas 66201).
NexGard (afoxolaner; Frontline Vet Labs, Division of Merial Limited, Athens, Georgia 30601). Parastar Plus for Dogs (fipronil, cyphenothrin; Novartis
Animal Health US, Inc, Greensboro North Carolina 27408). Revolution (does not kill Ixodes; selamectin; Zoetis Inc, Kalamazoo, Michigan 49007). Scalibor
Protector Band (deltamethrin; Merck Animal Health, Intervet Inc, Roseland, New Jersey 07068). Seresto (flumethrin, imidoclopramid; Bayer HealthCare
LLC, Animal Health Division, Shawnee Mission, Kansas 66201). Simparica (sarolaner; Zoetis Inc, Kalamazoo, Michigan 49007). Vectra 3D (dinotefuran,
permethrin, pyriproxyfen; CEVA US, Lenexa, Kansas 66215).
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ability of the spirochete to “hide” from the immune system in synovial
membranes, down-regulating their immunogenic surface proteins,152
and because of the existence of many strains for which there is no
cross-reacting immunity.99
The 3/6 panelists who dissented cited inconsistent efficacy
and duration of immunity (see above), cost, need for proper tick
control, lack of controlled studies with respect to tick control
when assessing vaccines in the field, theoretical concerns for
immune-mediated sequelae,1,153 and because most Bb-seropositive
dogs remain nonclinical, nonproteinuric carriers. The theoretical
concerns regarding future sensitization or aggravation of ICGN by
Bb vaccinal antigen-antibody circulating immune complexes (CIC),
proinflammatory OspA, or molecular mimicry of other Bb antigens
by self-proteins are difficult to study because of the lack of an
experimental model of Lyme nephritis, the difficulty in document-
ing true Lyme nephritis cases in the field, and the probable
genetic predisposition whereby Bb immune-complexes are not
cleared properly by the kidneys. The evidence for a negative
impact of vaccination remains anecdotal at best. It is unknown if
there is an underlying genetic podocytopathy,154 or some other
pathogenesis for Lyme nephritis. Fewer than 10% of suspected
Lyme nephritis cases had prior Bb vaccination (Richard Goldstein
[coauthor]. Personal communication) and their PLN may have
been because of other causes (eg, infectious, genetic, amyloidosis,
glomerulosclerosis) or vaccine failure. There is no known negative
impact of post-vaccinal Lyme-specific CICs, which increase transi-
ently after vaccination (8 weeks in vaccinated seronegative dogs;
to higher concentrations and longer in vaccinated seropositive
dogs).155,156
Statement: Panelists agreed that all dogs in Bb-endemic
areas (whether vaccinated or not) should receive
adequate tick control year-round, preferably with a
product that prevents tick attachment or rapidly kills
ticks during early feeding. Consensus for vaccination
was not reached. Three of 6 panelists recommend
vaccination, stating: (1) healthy Bb-seronegative dogs in
North American Bb-endemic regions may be vaccinated
with any of the currently available Bb vaccines and (2)
healthy (nonclinical, nonproteinuric) Bb-seropositive
dogs in those regions may be vaccinated if the risk of
reinfection is high. It is not recommended to vaccinate
sick or proteinuric dogs [EBM-D].
9 | SUMMARY
Our panel achieved consensus on evaluating all dogs at risk in North
America with a qualitative Bb antibody assay, testing all Bb-seropositive
dogs for proteinuria, using doxycycline as the first choice for dogs or
cats with suspected clinical LB (although the best protocol and duration
are unknown), using mycophenolate with or without prednisone in
Lyme nephritis suspects that are not responding to standard care, and
using tick control for all dogs and cats at risk (Table 8). Consensus was
not reached on whether to treat all Bb-seropositive dogs and cats,
TABLE 7 Available Bb vaccines in North America
Vaccine type Name of vaccine Adjuvant
Recombinant OspA (monovalent) Recombitek Lyme (Merial) No
Bivalent whole-cell inactivated bacterin (contains
one Osp A containing strain, one unique OspC-
producing strain, as well as other antigens)
LymeVax (Zoetis) Yes
Duramune Lyme (Elanco, formerly licensed to
Boehringer Ingelheim)
Yes
Nobivac Lyme (Merck) Yes
Chimeric recombinant (contains monovalent OspA
and 7 types of OspC from North American
strains)
Vanguard crLyme (Zoetis) Yes
TABLE 8 Summary of recommendations in consensus and not in consensus
Consensus Nonconsensus
Screening all dogs in Bb-endemic and emerging areas in North America Treating healthy nonclinical nonproteinuric Bb-seropositive dogs
Testing all Bb-seropositive dogs for proteinuria in North America
(frequency/duration debatable)
Using quantitative titers to decide about treatment
Choosing Doxycycline first choice for sick dogs at 10 mg/kg/dy for
1 month
How long to use antibiotics in Lyme nephritis suspects (1 month versus
3–6 months)
Using mycophenolate (6 short course prednisone) in Lyme nephritis
suspects that are not responding to antibiotics plus standard PLN
protocol
Use of Lyme vaccinations
Using tick control for all dogs at risk 6 month boostering of Lyme vaccines
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whether to use quantitative C6 antibody test results to guide treatment
recommendations or to follow treatment responses, how long to use
antibiotics for Lyme nephritis cases, and whether or not to use Bb vac-
cines, even in Bb-endemic areas.
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